GlassScriptPhysician profile
Sara P Freeman
NPI 1689983637
$57,379.87
in general payments reported to CMS, 2019-2025
57 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,396 · 2022: $3,771 · 2023: $14K · 2024: $12K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $16K · Consulting Fee: $14K · Food and Beverage: $14K · Travel and Lodging: $2,925 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $750 · Education: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $15,669.25 |
| Consulting Fee | $14,251.00 |
| Food and Beverage | $14,151.80 |
| Travel and Lodging | $2,925.10 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $750.00 |
| Education | $466.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33,238.12 | 2023-2025 | Sunosi, Symbravo |
| Harmony Biosciences LLC | $4,330.04 | 2021-2025 | Wakix |
| Abbvie INC. | $3,743.97 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $3,096.52 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,931.50 | 2021-2025 | Ajovy |
| Ipsen Innovation | $1,186.15 | 2023 | Dysport |
| Pfizer INC. | $785.59 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $729.77 | 2022-2025 | Dysport |
| Emd Serono, INC. | $696.07 | 2021-2025 | Mavenclad |
| Amgen INC. | $511.70 | 2021-2023 | Aimovig |
| Merz Pharmaceuticals, LLC | $442.88 | 2023-2025 | Xeomin |
| Lilly USA, LLC | $434.93 | 2022-2025 | Emgality, Reyvow, Zepbound |
| Lundbeck LLC | $411.52 | 2021-2024 | Vyepti |
| Novartis Pharmaceuticals Corporation | $407.93 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $340.95 | 2022-2023 | Quviviq |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.